

**RESPONSE TO RESTRICTION REQUIREMENT**  
**U.S. Appln. No. 10/029,862**

**IN THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

Claim 1. (Original) A method for identifying an endocrine disrupter comprising the steps of:

- (a) incubating a cell line having aromatase activity with a test compound;
- (b) assaying for inhibition or activation of aromatase activity due to said test compound so as to identify an endocrine disrupter.

Claim 2. (Original) The method of Claim 1, wherein said cell line is a human cell line.

Claim 3. (Original) The method of Claim 2, wherein said cell line is a human granulosa-like tumor cell line.

Claim 4. (Original) The method of Claim 3, wherein said cell line is a human granulosa-like tumor cell line has the following characteristics:

- (a) Origin: female invasive ovarian granulosa cell carcinoma;
- (b) Doubling time: 46.4 h;
- (c) Abnormal karyotype: 45, XX, 7q-, -22 (7q deletion and monosomy 22);
- (d) Possesses aromatase activity;
- (e) Produces progesterone upon exposure to human chorionic gonadotropin (HCG); and
- (f) Expresses follicle stimulating hormone (FSH).

Claim 5. (Original) The method of Claim 4, wherein said human cell line is KGN cell line (RIKEN gene bank deposit number: RCB 1154).

**RESPONSE TO RESTRICTION REQUIREMENT**  
**U.S. Appln. No. 10/029,862**

Claim 6. (Original) The method of Claim 1, wherein aromatase activity is assayed using an assay selected from the group consisting of a [ $^3\text{H}$ ]H<sub>2</sub>O release assay, an ELISA and an RIA.

Claims 7-14. (Cancelled).